124 related articles for article (PubMed ID: 34318397)
41. The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD).
Watanabe S; Manabe O; Hirata K; Oyama-Manabe N; Hattori N; Kikuchi Y; Kobayashi K; Toyonaga T; Tamaki N
BMC Cancer; 2016 Aug; 16():635. PubMed ID: 27528380
[TBL] [Abstract][Full Text] [Related]
42. Diagnosis and staging of cardiac masses: additional value of CMR with
Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
[TBL] [Abstract][Full Text] [Related]
43. Comparison of Contrast-Enhanced CT and [
Wagner F; Hakami YA; Warnock G; Fischer G; Huellner MW; Veit-Haibach P
Mol Imaging Biol; 2017 Oct; 19(5):795-803. PubMed ID: 28224325
[TBL] [Abstract][Full Text] [Related]
44. CXCR4-Directed PET/CT with [
Chen Z; Yang A; Zhang J; Chen A; Zhang Y; Huang C; Chen S; Yao S; Miao W
Mol Imaging Biol; 2022 Jun; 24(3):416-424. PubMed ID: 34651291
[TBL] [Abstract][Full Text] [Related]
45. Diagnostic Contribution of Contrast-Enhanced CT as Compared with Unenhanced Low-Dose CT in PET/CT Staging and Treatment Response Assessment of
Marchetti L; Perrucci L; Pellegrino F; Baroni L; Merlo A; Tilli M; Rambaldi I; Maietti E; Carnevale A; Bartolomei M; Giganti M
J Nucl Med; 2021 Oct; 62(10):1372-1379. PubMed ID: 33712534
[TBL] [Abstract][Full Text] [Related]
46. To Enhance or Not to Enhance? The Role of Contrast Medium
Massollo M; Fiz F; Bottoni G; Ugolini M; Paparo F; Puppo C; Provinciali N; Iacozzi M; Altrinetti V; Cistaro A; Cabria M; DeCensi A; Treglia G; Piccardo A
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34206116
[No Abstract] [Full Text] [Related]
47. FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.
Suenaga Y; Kitajima K; Ishihara T; Sasaki R; Otsuki N; Nibu K; Minamikawa T; Kiyota N; Sugimura K
Eur Radiol; 2016 Apr; 26(4):1018-30. PubMed ID: 26188656
[TBL] [Abstract][Full Text] [Related]
48. Utility of Volumetric Metabolic Parameters on Preoperative FDG PET/CT for Predicting Tumor Lymphovascular Invasion in Non-Small Cell Lung Cancer.
Li C; Tian Y; Shen Y; Wen B; He Y
AJR Am J Roentgenol; 2021 Dec; 217(6):1433-1443. PubMed ID: 33978465
[No Abstract] [Full Text] [Related]
49. The value of (18) F-FDG-PET/CT imaging in oral cavity cancer patients following surgical reconstruction.
Müller J; Hüllner M; Strobel K; Huber GF; Burger IA; Haerle SK
Laryngoscope; 2015 Aug; 125(8):1861-8. PubMed ID: 25892275
[TBL] [Abstract][Full Text] [Related]
50. Can full-dose contrast-enhanced CT be omitted from an FDG-PET/CT staging examination in newly diagnosed FDG-avid lymphoma?
van Hamersvelt HP; Kwee TC; Fijnheer R; Beek FJ; de Klerk JM; Nievelstein RA
J Comput Assist Tomogr; 2014; 38(4):620-5. PubMed ID: 24681861
[TBL] [Abstract][Full Text] [Related]
51. Multiparameter diagnostic model based on
Li C; Luan X; Bi X; Chen S; Pan Y; Zhang J; Han Y; Xu X; Wang G; Xu B
BMC Cancer; 2023 Feb; 23(1):119. PubMed ID: 36747196
[TBL] [Abstract][Full Text] [Related]
52.
Sibille L; Seifert R; Avramovic N; Vehren T; Spottiswoode B; Zuehlsdorff S; Schäfers M
Radiology; 2020 Feb; 294(2):445-452. PubMed ID: 31821122
[TBL] [Abstract][Full Text] [Related]
53. The role of 18F-FDG PET/CT in staging and restaging primary bone lymphoma.
Liu Y
Nucl Med Commun; 2017 Apr; 38(4):319-324. PubMed ID: 28225435
[TBL] [Abstract][Full Text] [Related]
54. Clinical features and
Chen D; Zhu Y; Chen Y; Zhu D; Liu Z; Li T; Liu Y; Zhao K; Su X; Li L
BMC Infect Dis; 2022 Jul; 22(1):646. PubMed ID: 35896979
[TBL] [Abstract][Full Text] [Related]
55. The prognostic value of
Grut H; Dueland S; Line PD; Revheim ME
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):218-225. PubMed ID: 29026950
[TBL] [Abstract][Full Text] [Related]
56. [Role of 18F-FDG PET/CT in comparison with CECT for whole-body assessment of patients with esophageal cancer.].
Altini C; Niccoli Asabella A; Lavelli V; Bianco G; Ungaro A; Pisani A; Merenda N; Ferrari C; Rubini G
Recenti Prog Med; 2019 Mar; 110(3):144-150. PubMed ID: 30968855
[TBL] [Abstract][Full Text] [Related]
57. Diagnostic performance and prognostic value of preoperative
Chen S; Zhao Y; Tang Q; Wu C; Wang A; Ma L; Zhang X; Chen J; Gao Y; Liao X; Feng N; Fan Y; Zhang J; Li X; Liu M
Cancer Imaging; 2022 Nov; 22(1):65. PubMed ID: 36435856
[TBL] [Abstract][Full Text] [Related]
58. CT and
Altinmakas E; Üçışık-Keser FE; Medeiros LJ; Ng CS
Acad Radiol; 2019 Jun; 26(6):e108-e114. PubMed ID: 30076085
[TBL] [Abstract][Full Text] [Related]
59. Retrospective analysis of the
Yang Y; Pan YQ; Wang M; Gu S; Bao W
Radiat Oncol; 2023 Dec; 18(1):196. PubMed ID: 38049843
[TBL] [Abstract][Full Text] [Related]
60. Pulmonary mucosa-associated lymphoid tissue lymphoma:
Albano D; Borghesi A; Bosio G; Bertoli M; Maroldi R; Giubbini R; Bertagna F
Br J Radiol; 2017 Nov; 90(1079):20170311. PubMed ID: 28830222
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
